These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9253789)

  • 21. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.
    Lazennec G; Ediger TR; Petz LN; Nardulli AM; Katzenellenbogen BS
    Mol Endocrinol; 1997 Aug; 11(9):1375-86. PubMed ID: 9259327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The functional interaction between HMGA1 and the estrogen receptor requires either the N- or the C-terminal domain of the receptor.
    Massaad-Massade L; Tacine R; Dulauroy S; Reeves R; Barouki R
    FEBS Lett; 2004 Feb; 559(1-3):89-95. PubMed ID: 14960313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics.
    Eng FC; Lee HS; Ferrara J; Willson TM; White JH
    Mol Cell Biol; 1997 Aug; 17(8):4644-53. PubMed ID: 9234721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
    Berrevoets CA; Doesburg P; Steketee K; Trapman J; Brinkmann AO
    Mol Endocrinol; 1998 Aug; 12(8):1172-83. PubMed ID: 9717843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.
    Carlson KE; Choi I; Gee A; Katzenellenbogen BS; Katzenellenbogen JA
    Biochemistry; 1997 Dec; 36(48):14897-905. PubMed ID: 9398213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription.
    Bollig A; Miksicek RJ
    Mol Endocrinol; 2000 May; 14(5):634-49. PubMed ID: 10809228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains.
    Métivier R; Penot G; Flouriot G; Pakdel F
    Mol Endocrinol; 2001 Nov; 15(11):1953-70. PubMed ID: 11682626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.
    Webb P; Nguyen P; Valentine C; Lopez GN; Kwok GR; McInerney E; Katzenellenbogen BS; Enmark E; Gustafsson JA; Nilsson S; Kushner PJ
    Mol Endocrinol; 1999 Oct; 13(10):1672-85. PubMed ID: 10517669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor mutants which do not bind 17 beta-estradiol dimerize and bind to the estrogen response element in vivo.
    Zhuang Y; Katzenellenbogen BS; Shapiro DJ
    Mol Endocrinol; 1995 Apr; 9(4):457-66. PubMed ID: 7659089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allosteric modulation of estrogen receptor conformation by different estrogen response elements.
    Wood JR; Likhite VS; Loven MA; Nardulli AM
    Mol Endocrinol; 2001 Jul; 15(7):1114-26. PubMed ID: 11435612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.
    Mahfoudi A; Roulet E; Dauvois S; Parker MG; Wahli W
    Proc Natl Acad Sci U S A; 1995 May; 92(10):4206-10. PubMed ID: 7753783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the AF-2/hormone-binding domain of the chimeric activator GAL4.estrogen receptor.VP16 inhibit hormone-dependent transcriptional activation and chromatin remodeling in yeast.
    Stafford GA; Morse RH
    J Biol Chem; 1998 Dec; 273(51):34240-6. PubMed ID: 9852087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators.
    Cho H; Katzenellenbogen BS
    Mol Endocrinol; 1993 Mar; 7(3):441-52. PubMed ID: 7683375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormone-dependent transactivation by estrogen receptor chimeras that do not interact with hsp90. Evidence for transcriptional repressors.
    Lee HS; Aumais J; White JH
    J Biol Chem; 1996 Oct; 271(42):25727-30. PubMed ID: 8824196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the yeast one-hybrid system to screen for mutations in the ligand-binding domain of the estrogen receptor.
    Bush SM; Folta S; Lannigan DA
    Steroids; 1996 Mar; 61(3):102-9. PubMed ID: 8852826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating Element.
    Arao Y; Coons LA; Zuercher WJ; Korach KS
    J Biol Chem; 2015 Jul; 290(28):17611-27. PubMed ID: 26028650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel, cell-type-specific mechanism for estrogen receptor-mediated gene activation in the absence of an estrogen-responsive element.
    Sukovich DA; Mukherjee R; Benfield PA
    Mol Cell Biol; 1994 Nov; 14(11):7134-43. PubMed ID: 7935428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor.
    Vegeto E; Allan GF; Schrader WT; Tsai MJ; McDonnell DP; O'Malley BW
    Cell; 1992 May; 69(4):703-13. PubMed ID: 1586949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.
    Fan S; Ma YX; Wang C; Yuan RQ; Meng Q; Wang JA; Erdos M; Goldberg ID; Webb P; Kushner PJ; Pestell RG; Rosen EM
    Oncogene; 2001 Jan; 20(1):77-87. PubMed ID: 11244506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.